Patents, clinical trials, and regulatory concerns with stimuli-responsive vesicular carriers

Abstract

Vesicular carriers, including liposomes, pharmacophores, and ethosomes, have risen as promising carriers focused on cancer management. Analysts and industry partners can employ these inventive carriers’ potential and significantly affect cancer treatment by understanding the practical prospects of vesicular carriers in cancer. Exploring the complex arena of patents, clinical trials, and regulatory perspectives is vital for effective advancement and commercialization. Patents are imperative in ensuring intellectual property rights, but the apparent scene is complex and continually advancing. This chapter enlightens us on the present status and challenges associated with the grant of patents, particularly vesicular carriers. Clinical trials are vital for proving safety and efficacy, but designing and conducting these trials could be a noteworthy challenge. In this chapter, the clinical trials section looks into the different phases of trials, counting phases I–III, and exhibits the cluster of nano-formulations right now underneath examination. Regulatory aspects, comprising challenges faced by the Food and Drug Administration (FDA) and other worldwide regulations, are also summarized in the chapter, followed by a discussion on the FDA’s approach to regulating nanotechnology products taken after a global snapshot of nanomedicine direction, including the European Union, United States, United Kingdom, Canada, Japan, and India. This chapter outlines the current state of vesicular carriers in cancer, including patents, clinical trials, and regulatory aspects. It highlights the challenges and openings in this field and gives experiences for analysts and industry partners to explore this complex scene.